Related Experiment Video
Updated: May 23, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy
1From The University of Texas MD Anderson Cancer Center, Houston, Texas.
The treatment landscape for advanced-stage Hodgkin lymphoma (HL) continues to evolve, with immune checkpoint inhibitors now pivotal to improving patient outcomes. One of the most promising developments is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This novel approach has demonstrated encouraging efficacy and is increasingly integrated into frontline treatment regimens. This article provides practical, evidence-based knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD. It reviews the most frequently observed adverse events, including immune-mediated events, and outlines best practices for monitoring and management. A real-world case study illustrates how proactive management and clinical judgment can influence outcomes in patients receiving nivolumab-AVD.
The treatment landscape for advanced-stage Hodgkin lymphoma (HL) continues to evolve, with immune checkpoint inhibitors now pivotal to improving patient outcomes. One of the most promising developments is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This novel approach has demonstrated encouraging efficacy and is increasingly integrated into frontline treatment regimens. This article provides practical, evidence-based knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD. It reviews the most frequently observed adverse events, including immune-mediated events, and outlines best practices for monitoring and management. A real-world case study illustrates how proactive management and clinical judgment can influence outcomes in patients receiving nivolumab-AVD.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Tumor Immunotherapy
Treatment Resistant Cancers
Drug Toxicity: Overview

